At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Mar 16, 2026 at 08:15 ET
Amarin Corporation announced that additional subgroup and mechanistic data from the REDUCE-IT trial will be presented at the American College of Cardiology's 2026 Scientific Session. The data include analyses on icosapent ethyl's efficacy in high-risk cardiovascular patients and its effect on lipoprotein(a) oxidation, reinforcing the drug's biologic activity beyond triglyceride lowering.
- Additional REDUCE-IT subgroup and mechanistic data will be presented at ACC 2026 in New Orleans (March 28–30, 2026).
- Oral presentation on icosapent ethyl efficacy in extreme cardiovascular risk patients scheduled for March 29.
- Poster on EPA’s inhibition of oxidized lipoprotein(a) at elevated levels to be presented March 28.
- No new financial results, guidance changes, regulatory decisions, or commercial updates were disclosed.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access